Archive
1250 articles, sorted by publication time.
The companies will embed generative AI in ICON’s Orbis platform, extending from research-site screening to early warnings of enrollment risks. The use cases have taken concrete shape, but accuracy, validation methods, and actual time savings have not yet been disclosed.
A spatial genomics study in mice shows that the reparative tissue environment after colitis is not merely a passive response to damage, but may also select for and amplify cell clones carrying oncogenic mutations, proposing a testable mechanism for the initiation of inflammation-associated colorectal cancer.
The treatment, tailored for a child with a rare disease, ended in her death seven days after injection; the serious adverse event, which emerged only more than a year later, has also brought animal safety signals, family funding, and clinical oversight under scrutiny.
In 45 stored plasma samples, the battery-powered platform achieved 93.3% sensitivity among interpretable samples; however, 17 invalid results reduced end-to-end performance, showing that key engineering challenges remain before true self-testing is possible.
A prospective study at six New York clinics found that iPredict-AMD could identify age-related macular degeneration requiring ophthalmic evaluation. However, only 696 of the 845 recruited participants were included in the primary analysis, and its performance across regions and clinical benefits remain to be validated.
Although radiotherapy may trigger a systemic immune response, unirradiated tumors often escape attack. A new study spanning mouse models, human lung cancer specimens, and single-cell analysis points to cancer-associated fibroblasts that secrete SFRP2.
In a 300-participant, multicenter randomized trial, the top-five gene prediction hit rate rose from 67.3% to 88.5% when ophthalmology experts used Retina4IRD to interpret fundus images. The findings suggest that AI could help triage rare disease testing, but cannot yet replace genetic sequencing.
While preserving the spatial organization of tissue, the research team simultaneously observed DNA, RNA, and proteins, finding that the chromatin loop extrusion mechanism is an important condition for B cells to initiate somatic hypermutation.
The research team enabled antibodies to recognize KRAS mutation fragments displayed on the surface of cancer cells and direct immune attacks in cell-based experiments. This new approach is supported by structural and functional evidence, but remains limited by HLA type and has not yet entered human studies.
Gwyn Lo offers a combined hormonal contraceptive option that is replaced once weekly and delivers a lower estrogen dose; a Phase 3 trial supports its contraceptive efficacy and adhesion performance, but it is indicated only for women with a BMI below 30 kg/m² who are eligible to use combined contraceptives.
mocertatug rezetecan has advanced into a pivotal confirmatory stage based on tumor response signals from an early-stage study; the new trial will directly compare it with current treatments, but whether it can delay progression, extend survival, and maintain acceptable safety remains to be answered by randomized data.
After completing its merger with VYNE and securing approximately $200 million in funding, Yarrow has begun testing an antibody that directly blocks TSHR; the first proof-of-concept data are expected in the second half of 2027.